Peptide News Digest

GLP-1 Aging Data at ARDD 2026, AI-Designed Gut Peptides, an Amylin Brain Circuit, Zealand Completes Buyback

Lilly and Novo bring GLP-1 aging data to ARDD 2026, AI-designed gut peptides cut weight in rats, and Penn maps an amylin brain circuit.

7 stories · Covering research, industry

Editor's Note

Tuesday's verified news was mostly early-stage science, and most of it measures something short of a clinical outcome. At the ARDD aging meeting, Novo and Lilly showed that semaglutide and tirzepatide move protein and DNA markers of biological age, but those clocks are proxies, and Lilly's own epigenetic substudy had no control group. A small Italian study reported that tirzepatide cut fat mass while sparing skeletal muscle, though it used bioimpedance, had no comparison group, and paired the drug with diet and exercise. Outside the incretin drugs, Lembas Bio used AI to design oral peptides that make the gut release more of its own GLP-1, a Penn team traced a brain pathway through which amylin curbs eating, and a review mapped peptides that light up liver tumors on scans, all of it still in cells or animals. Zealand Pharma, whose petrelintide entered Phase 3 last month, finished a DKK 1.3 billion share buyback ahead of schedule.

Research

Lilly and Novo Bring GLP-1 Aging Data to ARDD 2026: Semaglutide Lowered a Protein-Based 'Heart Age' Estimate by About 2 to 4 Years Across Five Trials

At the Aging Research and Drug Discovery (ARDD) meeting at Harvard on October 1-3, 2026, Novo Nordisk researchers reported that in protein data from 10,052 participants in five semaglutide trials, the drug lowered an estimate of heart biological age by about 2 to 4 years at the first follow-up measurement, according to the meeting's poster abstracts. Longevity.Technology reported on October 4 that Novo also modeled SELECT trial results in a UK cohort of 19,117 people to project 1.9 life-years gained, and that a Lilly epigenetic substudy with 71 paired SURMOUNT-5 participants found all 15 epigenetic clocks showed less aging than the 1.38 years that had passed, two of them statistically significant. Lilly called its work preliminary and hypothesis-generating, with no placebo or control group, and biological-age clocks are not established clinical outcomes.

#semaglutide #tirzepatide #longevity #novo-nordisk #eli-lilly
Research

Six Months of Tirzepatide Cut Fat Mass 35% With Skeletal Muscle Preserved in a 122-Patient Italian Real-World Study

A retrospective study from two centers in Palermo, Italy, published online September 25, 2026 in the Journal of Diabetes and Its Complications and reported by News-Medical on October 2, followed 122 adults with overweight or obesity and no diabetes who took tirzepatide alongside a standardized low-carbohydrate diet and tailored exercise. After 24 weeks, at a mean final dose of 5.32 mg, average weight fell from 95 kg to 80 kg, fat mass fell 35.4% and fat-free mass 5.1% on bioelectrical impedance, and the authors reported that skeletal muscle was preserved. The study had no control group, used bioimpedance rather than DXA scans, and included only people who completed the 24 weeks.

#tirzepatide #body-composition #muscle-preservation #real-world-evidence
Research

Survey of 760 U.S. Clinicians Finds Far Less Familiarity With GIP and Glucagon Receptor Drugs Than With GLP-1s for MASH

An online survey of 760 U.S. hepatologists and gastroenterologists, endocrinologists, and primary care clinicians, conducted from November 2024 to January 2025 and published October 6, 2026 in Clinical and Translational Gastroenterology, found that 76.8% were very or extremely familiar with the GLP-1 receptor, compared with 53.9% for the GIP receptor and 30.1% for the glucagon receptor. Most still expected each type of agonist to help people with MASH: 90.3% for GLP-1, 75.9% for GIP, and 87.0% for glucagon receptor agonists. One author is a Boehringer Ingelheim employee; Boehringer is developing survodutide, a GLP-1 and glucagon dual agonist, for MASH.

#mash #masld #glp-1 #boehringer-ingelheim
Research

Lembas Bio and Tel Aviv University Use AI to Design Oral Peptides That Raise GLP-1 Release and Cut Weight in Obese Rats

Researchers at Lembas Bio and Tel Aviv University reported in ACS Nutrition Science on October 6, 2026 an AI-guided design pipeline, built on AlphaFold2 structural modeling, for peptides that act on nutrient-sensing receptors of the gut cells that release the hormone GLP-1. After four rounds of design and screening, lead peptides raised GLP-1 secretion more than 27-fold in a mouse gut cell line, exceeding an optimized small-molecule GLP-1 secretagogue, and 28 days of oral dosing reduced food intake and body weight in diet-induced obese rats, with semaglutide as an active comparator. The authors present the work as a route to nutritional ingredients, and the results so far come from cells and rats.

#ai-drug-design #oral-peptide #glp-1-secretion #preclinical
Research

Penn Researchers Trace an Amylin Brain Circuit From a Reward-Linked Brainstem Region That Curbs Eating in Mice and Rats

A University of Pennsylvania psychiatry team reported in Diabetes, Obesity and Metabolism on October 6, 2026 that neurons carrying the amylin-responsive calcitonin receptor in the laterodorsal tegmental nucleus, a brainstem region tied to reward and motivation, project to the ventral tegmental area in both mice and rats. Knocking down the receptor along that pathway weakened the appetite-suppressing effect of injected salmon calcitonin, which activates amylin receptors, and chemically switching the pathway on reduced food intake and body weight in mice. The findings come from rodents and help explain how amylin signaling reduces food intake.

#amylin #calcitonin #neuroscience #preclinical
Research

Review Maps Two Decades of Glypican-3-Targeting Peptides for Imaging Liver Cancer

A review from the Indian Institute of Technology Ropar, published October 4, 2026 in the Journal of Peptide Science, surveys linear and cyclic peptides that bind glypican-3, a cell-surface protein that is common in hepatocellular carcinoma but largely absent from normal adult liver. The peptides, found mainly through phage display and structure-guided design, have enabled PET, SPECT, and fluorescence imaging of liver tumors in preclinical models, and albumin-binding changes and cyclization have improved tumor-to-liver contrast and stability. The authors argue that small peptides penetrate tumors faster and clear more quickly than the antibodies used against the same target; the imaging work they review is preclinical.

#liver-cancer #peptide-imaging #phage-display #cyclic-peptide
Industry

Zealand Pharma Completes DKK 1.3 Billion Share Buyback Early, Repurchasing 4.4 Million Shares

Zealand Pharma said on Monday, October 5, 2026 that its share buyback program, launched May 7 at about DKK 1.3 billion (roughly $200 million), was completed ahead of its October 31 deadline after lead manager Danske Bank closed it once the full amount was reached. Zealand bought back 4,408,500 shares at an average price of DKK 294.88 and now holds 5,279,342 treasury shares, about 7.37% of its share capital. The Danish peptide company's lead obesity drug, the amylin analog petrelintide partnered with Roche, entered Phase 3 on September 22.

#zealand-pharma #petrelintide #share-buyback

Related Guides